Updated Jul 16, 2026
Vitt Daniel has filed 1 SEC Form 4 filing across 1 company in the last 90 days — buying. Lifetime open-market purchases: $12K.
Daniel Vitt is the CEO and a Director of Immunic Inc., a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory and autoimmune diseases. He has held multiple roles within the company and has been involved in its strategic direction.
| Role | Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-06-04 | IMUX | IMMUNIC, INC. | P — Open-market purchase | 15.0K | $0.77 | $12K |
Daniel Vitt is the CEO and a Director of Immunic Inc., a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory and autoimmune diseases. He has held multiple roles within the company and has been involved in its strategic direction.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 1 open-market purchases ($12K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Vitt Daniel profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.